104994-90-3

Basic information

• Product Name: Benzenamine, 2-methoxy-5-(2-pyridinyl)-
• CAS NO: 104994-90-3
• Molecular Formula: C12H12N2O
• Molecular Weight: 200.24
• Mol File: 104994-90-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-methoxy-5-(2-pyridinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-methoxy-5-(2-pyridinyl)-(104994-90-3)
• EPA Substance Registry System: Benzenamine, 2-methoxy-5-(2-pyridinyl)-(104994-90-3)

Safety Data

• Hazardous Substances Data: 104994-90-3(Hazardous Substances Data)

Upstream product

• 110-86-1 pyridine 
• 33696-00-3 4-bromo-1-methoxy-2-nitrobenzene 
• 197958-29-5 pyridin-2-ylboronic acid 
• 159958-44-8 2-(4-hydroxy-3-nitrophenyl)pyridine 
• 167959-18-4 4-(2-pyridyl)-2-nitroaniline 
• 104-94-9 4-methoxy-aniline 
• 4394-02-9 2-(4-methoxy-3-nitrophenyl)pyridine 
• 5957-90-4 4-(2-pyridinyl)anisole 

Downstream Products

• 158461-72-4 [2-(2-Methoxy-5-pyridin-2-yl-phenylcarbamoyl)-1-methyl-ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

Synthesis and antiarrhythmic activity of disubstituted phenylpyridine derivative

A series of disubstituted phenylpyridine derivatives was synthesized and their antiarrhythmic effects against chloroform-induced ventricular arrhythmias in mice were examined. Among them, 2- and 3-[2-(3- aminobutyramido)-4-(2,2,2-trifluoroethoxy)phenyl]pyridines (23h, 24h) and 3- [2-(3-aminobutyramido)-4-ethoxyphenyl]pyridine (24i) showed potent antiarrhythmic activity. They had approximately twice the potency of mexiletine (III). Compound 24i was selected from this series as a candidate for further development; it was found to have a class I B electrophysiological character and to show a slow kinetic rate-dependent block (RDB) of the sodium channel in cardiac muscle.